Skip to content

Peptide COA watchdog · Evidence-led case files · Corrections welcomed

The COA Catcher home

The COA Catcher

Evidence has a trail. We follow it.

Documented case record

Lazarus Labs — Two Batch Codes, No Visible Link

Published or last materially updated:

Case scope matters. This record concerns the product, batch, transaction, or evidence identified in the article. It should not be read as a finding about every product sold by a vendor, or as proof of intent or illegality. Review the source material, limitations, status, and any response together.

Case evidence details

Evidence published Suspected document or authentication issue

The publisher has posted sources concerning the specific product or batch described. Readers should assess the cited material and any vendor response.

Cited material raises a document-authenticity or provenance concern; it is not an official finding unless separately stated.

Annotated evidence graphic for Lazarus Labs — Two Batch Codes, No Visible Link
Annotated evidence graphic. The material findings are repeated in the text below.
Vendor URL (reference only)
www.lazaruslabs.com.au
Seller identity at the time
Lazarus Labs (lazaruslabs.com.au)
Last reviewed
Product / batch scope
Tesamorelin 10 mg COA presented for Lazarus batch LL-TESAMORELIN-0125
Sample / order date
Batch / lot / order ID
Supplier batch CS-te10-0111; Lazarus vial batch LL-TESAMORELIN-0125

Chain of custody and provenance

WHAT LAZARUS SHOWS

Lazarus’s Certificate Inspector places vial batch LL-TESAMORELIN-0125 (“on your vial”) beside Janoshik report batch CS-te10-0111 (“report only”).

WHAT THE DOWNLOAD REVEALS

The downloaded certificate shows CS-te10-0111, but its task number, client, manufacturer and unique verification key are blacked out. Nothing visible in the published material maps LL-TESAMORELIN-0125 to the sample Janoshik tested.

Evidence summary

TWO BATCH CODES. THEN THE IDENTIFIERS DISAPPEAR.

At first glance, the page looks reassuring: a Janoshik certificate displayed beside the Lazarus vial batch. Look closer and the numbers split. The vial is labelled LL-TESAMORELIN-0125. The report is for CS-te10-0111.

So we followed the trail and downloaded the certificate.

That is where the useful identifiers disappear. The task number is blacked out. Client and Manufacturer are blacked out. The unique key needed for Janoshik verification is blacked out. The report still shows Tesamorelin 10MG, batch CS-te10-0111, 11.41 mg and 99.704% purity—but it does not show the link to the Lazarus-labelled vial.

The lab result may be genuine. The missing step is the one that matters to the buyer: visible proof that the vial batch and tested sample are the same material.

REPORT SHOWN. LAZARUS BATCH LINK NOT SHOWN.

Sources and references

  1. https://janoshik.com/verification/?key=GI8BTN1JNPFL&task=100571
  2. https://verify.janoshik.com/tests/100571-tesamorelin_10mg_cocer_peptides_GI8BTN1JNPFL
  3. https://www.lazaruslabs.com.au/wp-content/uploads/2026/04/902b4ddd6c5e485aa2682b5a4e9963e5-LL-TESAMORELIN-0125.png
  4. https://www.lazaruslabs.com.au/certificate-of-analysis/?certificate=ll-tesamorelin-0125
  5. https://www.lazaruslabs.com.au/product/tesamorelin-10mg/

Laboratory test details

Laboratory
Janoshik Analytical
Method
Assessment of a peptide vial, as described on the Janoshik report
Report / finding date

Result as reported

Task #100571. Client: Cocer Peptides. Manufacturer: cocerpeptides.com. Sample: Tesamorelin 10mg Cocer Peptides. Batch: CS-te10-0111. Result: 11.41 mg. Purity: 99.704%. Unique key: GI8BTN1JNPFL.

Vendor response

No vendor response was requested or received as at 25 August 2026. The COA Catcher correction and contact channel remains available for evidence-based corrections or a vendor response.

Limitations and uncertainty

This evidence does not show that the Janoshik report is fabricated and does not establish the composition of every Lazarus product. It shows that this report identifies Cocer Peptides and supplier batch CS-te10-0111, not Lazarus or Lazarus batch LL-TESAMORELIN-0125. The chain of custody between those batches is not established by the cited material.

Editorial review record

Source authentication
Scientific review
Privacy / redaction review
TGA advertising review

Public change log

25 August 2026 — Added an annotated evidence walkthrough and rewrote the case summary around the visible batch and verification trail.

Operator disclosure

Readers should assess the cited primary sources independently. Corrections, context and additional evidence may be submitted through the right-of-reply process.

Scope note: this record concerns only the cited product, batch, transaction, and source material. It is not a blanket judgment about every product or activity of the named vendor, and it is not a legal determination.

Absence from this directory is not evidence that a vendor or product is safe, genuine, lawful, or suitable.

Reading this record

Evidence: Open the cited material where available; a summary is not a substitute for the source.

Status: Check whether the case is under review, published with limitations, corrected, or closed.

Response: Vendor context and disputes should be clearly labelled and presented with the record.

Updates: Material changes should be dated in the correction history.

Read the methodology

Correction or right of reply

If you are named or materially affected by this record, you can challenge an error, add context, or provide an on-record response. Material corrections are dated and remain visible.

Review the right-of-reply process